Health and Me

Rachel V Thomas

Roche Pharma Launches 7-Minute Injectable Immunotherapy For Lung Cancer In India

In a major development for <span><a href="https://www.healthandme.com/health/cancer">cancer</a> care</span> in India, Swiss pharmaceutical major <span>Roche Pharma</span> has launched <span>Tecentriq SC</span>, the country’s first subcutaneous (under-the-skin) <span>immunotherapy</span> for <span><a href="https://www.healthandme.com/health/lung-cancer">lung cancer</a></span> that can be administered in approximately seven minutes.

While conventional intravenous (IV) infusions can take hours, <span>Tecentriq</span> SC can significantly improve the <span><a href="https://www.healthandme.com/health/cancer">cancer</a></span> treatment experience by reducing treatment time by nearly 80 per cent.

The seven-minute injectable immunotherapy has the potential to:

<ul><li>Treat up to five patients in the time taken to treat one patient through intravenous infusion</li><li>Help optimise healthcare resources</li><li>Lower indirect treatment costs</li><li>Minimise the need for patients to travel long distances</li><li>Reduce the amount of time caregivers spend in hospitals</li></ul>

“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.

<h2>What Is Tecentriq SC? What's The Cost In India?</h2>

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.

First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.

In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases. 

 According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".  

<strong>Also read: </strong><a href="https://www.healthandme.com/health-news/india-gets-its-first-alzheimers-drug-know-all-about-eli-lillys-lormalzi-article-154316399" data-type="tilCustomLink">India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi</a>

Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.

The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.

<h2>How Tecentriq SC will Boost Cancer Care In India</h2>

The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.

“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.

<strong>Read More: </strong><a href="https://www.healthandme.com/health-wellness/india-better-prepared-for-hantavirus-outbreaks-after-covid-19-experience-says-dr-nk-ganguly-exclusive-article-154312148" data-type="tilCustomLink">India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | Exclusive</a>

Global studies have indicated strong patient preference for subcutaneous administration.

According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:

<ul><li>Four out of five patients preferred Tecentriq SC over IV administration</li><li>Patients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preference</li></ul>

Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.

In the IMscin001 study presented at ESMO 2023:

<ul><li>90 per cent of healthcare professionals agreed the SC formulation was easy to administer</li><li>75 per cent believed it could save time for healthcare teams.</li></ul>

Health Conditions A-Z

health

roche-pharma-launches-7-minute-injectable-immunotherapy-for-lung-cancer-in-india

Roche Pharma

Immunotherapy

Lung Cancer

Tecentriq SC

Tecentriq

cancer care

cancer

non small cell lung cancer

Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health

Global Health Progress Remains ‘Fragile And Insufficient’, Warns WHO

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.The seven-minute injectable immunotherapy has the potential to:Treat up to five patients in the time taken to treat one patient through intravenous infusionHelp optimise healthcare resourcesLower indirect treatment costsMinimise the need for patients to travel long distancesReduce the amount of time caregivers spend in hospitals“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.What Is Tecentriq SC? What's The Cost In India?Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.  According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".  Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s LormalziHow Does Tecentriq SC Work?Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.How Tecentriq SC will Boost Cancer Care In India The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.Read More: India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | ExclusiveTecentriq SC: SafetyGlobal studies have indicated strong patient preference for subcutaneous administration.According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:Four out of five patients preferred Tecentriq SC over IV administrationPatients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preferenceStudies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.In the IMscin001 study presented at ESMO 2023:90 per cent of healthcare professionals agreed the SC formulation was easy to administer75 per cent believed it could save time for healthcare teams.

roche pharma launches 7-minute injectable immunotherapy for lung cancer in india

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Roche Pharma Launches 7-Minute Injectable Immunotherapy For Lung Cancer In India

Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health

Global Health Progress Remains ‘Fragile And Insufficient’, Warns WHO

Polyendocrine Metabolic Ovarian Syndrome — PMOS: The New Name for PCOS

Health Conditions A-Z

Roche Pharma Launches 7-Minute Injectable Immunotherapy For Lung Cancer In India

Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health

Global Health Progress Remains ‘Fragile And Insufficient’, Warns WHO